Notes from the front lines of the battle against H1N1. So, I've spent part of yesterday and most of today at the University of Kansas Hospital covering the first H1N1 flu shots being administered.    Read More

This Friday the CDC is expected to start giving weekly updates on where and how much H1N1 vaccine has been shipped. I'm curious what the demand will truly turn out to be. Some people are growing concerned about the increasing number of pediatric deaths from H1N1 and may rush to get their kids and themselves vaccinated. Others are afraid of or paranoid about the vaccine.    Read More

Yesterday and today thousands of kids and healthcare workers around the country started getting AstraZeneca's H1N1 FluMist, the vaccine that's sprayed into the nose. The first shots from Novartis and Sanofi-Aventis may be available later this week. GlaxoSmithKline and Baxter are still waiting for the FDA to approve their vaccines.    Read More

The CDC announced today that healthcare workers in Tennessee and Indiana would be amongst the first to get swine flu vaccinations.  The outbreak of the H1N1 swine flu virus has sadly killed over 3,900 peope per a report by the World Health Organization (WHO) on September 25th.  At the same time the race to battle the pandemic has propped up the shares of biotech companies that promise solutions.   Read More

Of the many issues facing Corporate America this fall, none seems more pressing than vaccinating workers against swine flu.   Read More

The drug biz is abuzz over social media. It's the new frontier. For a lot of PR and corporate communications teams it's all about new media and social media. Some biopharmas, big and small, now have directors of social media. Most are still trying to find their way, but the Food and Drug Administration may soon direct them.    Read More

When it rains, it pours. I mean, what a crazy Monday for deals and data in biopharma.    Read More

Stocks rallied for the month of August but fell on Monday as concerns about the global economy weighed on Wall Street. What must you know about this market?   Read More

After a long delay, Eli Lilly finally launched its new bloodthinner Effient just this month. But analysts are already buzzing about what's next.    Read More

Cramer makes the call on viewers' favorite stocks.   Read More